In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.

Florence Kurttila brings a patient’s insights to the world of colon cancer research.

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

The way we develop new treatments for cancer does always lead to better survival time, and rarely leads to better quality of life.

Several studies focused on this topic were recently reported on at the AACR-Melanoma Conference.

Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.

First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.

Isatuximab improved progression-free survival in a Phase III study.